August 2012
-
Acadia Pharmaceuticals announced that it will develop ACP-101 (formerly LV-101) intranasal carbetocin for the treatment of excessive hunger in Prader-Willi syndrome (PWS). Acadia acquired the rights to the nasal spray when it acquired Levo Therapeutics… Read more . . .
-
Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it… Read more . . .
-
Dutch device company Gilbert Technologies has announced the closing of a €7 million funding round led by DeepTechXL. The company said that Brabant Startup Funds also converted its earlier loan to Gilbert Technologies, making Brabant… Read more . . .
-
Vistagen announced that a Phase 2a trial of the company’s PH80 intranasal epoxyestrenolone in menopausal women experiencing hot flashes demonstrated statistically significant reduction in the frequency and severity of the hot flashes. The company acquired PH80… Read more . . .
-
Australian inhaled cannabis developer InhaleRx (formerly Lifespot Health) announced the initiation of a Phase 1 SAD study of the company’s IRX211 inhaled dronabinol, a synthetic THC. According to the company, IRX211 was formulated by “a… Read more . . .
-
Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced… Read more . . .
-
According to Oragenics, Canadian biopharmaceutical research consortium CQDM has awarded a grant for development of variant-agnostic protein antigens for use in an intranasal COVID-19 vaccine that “aims to build upon Oragenics’ current lead intranasal vaccine… Read more . . .
-
Aerami Therapeutics has announced the promotion of Joshua Ziel from Chief of Staff and VP, Program Development to Chief Operating Officer and interim CEO. Executive Chairwoman Anne Whitaker had been leading Aerami since the sudden… Read more . . .
-
After pausing for several years due to the COVID-19 pandemic, the 2023 edition of Aerosol School will take place virtually. Students will have access to more than 200 hours of lectures from well-known experts on… Read more . . .
-
Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company’s Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.